These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 35337110)

  • 1. Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer and Dementia.
    Top WMC; Kooy A; Stehouwer CDA
    Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus.
    Anfossi G; Russo I; Bonomo K; Trovati M
    Curr Vasc Pharmacol; 2010 May; 8(3):327-37. PubMed ID: 19485923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin: Is it Still the First Line in Type 2 Diabetes Management Algorithm?
    Grammatiki M; Sagar R; Ajjan RA
    Curr Pharm Des; 2021; 27(8):1061-1067. PubMed ID: 33355048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Current and Potential Therapeutic Use of Metformin-The Good Old Drug.
    Drzewoski J; Hanefeld M
    Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33562458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis.
    Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Raparelli V; Pilote L
    Int J Cardiol; 2020 Jul; 310():147-154. PubMed ID: 32303419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus.
    Li T; Providencia R; Mu N; Yin Y; Chen M; Wang Y; Liu M; Yu L; Gu C; Ma H
    Cardiovasc Diabetol; 2021 Jan; 20(1):30. PubMed ID: 33516224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Early intensification of glucose-lowering therapy: VERIFY lessons and real clinical practice on the example of the Moscow region diabetes register data].
    Misnikova IV; Kovaleva YA; Gubkina VA
    Probl Endokrinol (Mosk); 2020 Dec; 66(5):86-95. PubMed ID: 33369376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical benefits of metformin in gynecologic oncology.
    Imai A; Ichigo S; Matsunami K; Takagi H; Yasuda K
    Oncol Lett; 2015 Aug; 10(2):577-582. PubMed ID: 26622536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of metformin on the myocardial tolerance to ischemia-reperfusion injury in the rat model of diabetes mellitus type II.
    Kravchuk E; Grineva E; Bairamov A; Galagudza M; Vlasov T
    Exp Diabetes Res; 2011; 2011():907496. PubMed ID: 21754920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin: historical overview.
    Bailey CJ
    Diabetologia; 2017 Sep; 60(9):1566-1576. PubMed ID: 28776081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin: Activation of 5' AMP-activated protein kinase and its emerging potential beyond anti-hyperglycemic action.
    Goel S; Singh R; Singh V; Singh H; Kumari P; Chopra H; Sharma R; Nepovimova E; Valis M; Kuca K; Emran TB
    Front Genet; 2022; 13():1022739. PubMed ID: 36386794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin as first choice in oral diabetes treatment: the UKPDS experience.
    Holman R
    Journ Annu Diabetol Hotel Dieu; 2007; ():13-20. PubMed ID: 18613325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin: New Preparations and Nonglycemic Benefits.
    Fujita Y; Inagaki N
    Curr Diab Rep; 2017 Jan; 17(1):5. PubMed ID: 28116648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of metformin on haemostasis and vascular function in man.
    Grant PJ
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S44-52. PubMed ID: 14502100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.